Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Cash from Financing Activities (2020 - 2024)

RAPT Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at $143.1 million for Q4 2024.

  • For Q4 2024, Cash from Financing Activities rose 31147.82% year-over-year to $143.1 million; the TTM value through Dec 2024 reached $152.9 million, up 10463.37%, while the annual FY2024 figure was $152.9 million, 10463.37% up from the prior year.
  • Cash from Financing Activities for Q4 2024 was $143.1 million at RAPT Therapeutics, up from $701000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $143.1 million in Q4 2024 and bottomed at $106000.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $864000.0 (2020), against an average of $26.4 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 99.39% in 2023 before it surged 31147.82% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.6 million in 2020, then plummeted by 86.82% to $601000.0 in 2021, then soared by 12438.94% to $75.4 million in 2022, then tumbled by 99.39% to $458000.0 in 2023, then soared by 31147.82% to $143.1 million in 2024.
  • Per Business Quant, the three most recent readings for RAPT's Cash from Financing Activities are $143.1 million (Q4 2024), $701000.0 (Q2 2024), and $9.0 million (Q1 2024).